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Abstract 
Both metabolism and transport are key elements defining the bioavailability and biological activity of molecules, i.e. 
their adverse and therapeutic effects. Structured and high quality experimental data stored in a suitable container, 
such as a relational database, facilitates easy computational processing and thus allows for high quality information/
knowledge to be efficiently inferred by computational analyses. Our aim was to create a freely accessible database 
that would provide easy access to data describing interactions between proteins involved in transport and xenobiotic 
metabolism and their small molecule substrates and modulators. We present Metrabase, an integrated cheminfor-
matics and bioinformatics resource containing curated data related to human transport and metabolism of chemi-
cal compounds. Its primary content includes over 11,500 interaction records involving nearly 3,500 small molecule 
substrates and modulators of transport proteins and, currently to a much smaller extent, cytochrome P450 enzymes. 
Data was manually extracted from the published literature and supplemented with data integrated from other avail-
able resources. Metrabase version 1.0 is freely available under a CC BY-SA 4.0 license at http://www-metrabase.ch.cam.
ac.uk.
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Background
Absorption, distribution, metabolism and excretion 
(ADME) properties of small molecules are vitally impor-
tant for their function and potential toxicity, hence under-
standing their interaction with transport proteins as well 
as metabolizing enzymes is fundamental to the discovery 
and development of e.g. safe, efficacious medicines and 
skin products. However, this data is largely dispersed 
across the literature, with fractions of the data available in 
current open and proprietary databases. Numerous valu-
able publicly available transporter-related data sources 
exist that are either specific to membrane transporters 
(e.g. TP-search [1], UCSF-FDA TransPortal [2], TSdb 
[3], Human Transporter Database [4], HMTD [5], TCDB 
[6], SLC Tables [7] and Membrane Proteins of Known 
3D Structure [8]) or contain transporter data as part of 
a broader collection of biological and pharmacologi-
cal data (e.g. ChEMBL [9], HMDB [10], DrugBank [11], 
Transformer [12], KEGG [13], Recon X [14], PharmGKB 
[15], UniProt [16], CTD [17] and TTD [18]), but most 
of these databases do not include the additional related 
data (e.g. tissue expression) and metadata required for 
in-depth cheminformatics analyses. Ligand-based stud-
ies, however, often remain the main or only option for 
modeling transport proteins as targets, since there are 
not many 3D structures of small molecule transporters 
available, especially for human proteins. Moreover, since 
these are very flexible proteins [19–21], analyses involv-
ing the dynamics of the multiple transporter systems is 
often complex and often beyond the scope of presently 
available simulation capabilities. Nonetheless, quick and 
convenient access to chemical structures is often missing 
in these resources and sometimes only chemical names 
are provided, e.g. UCSF-FDA TransPortal (focused on 
FDA-approved drugs) and Transformer (focused on bio-
transformations of xenobiotics). In QSAR modeling and 
other cheminformatics applications however, molecular 
properties are typically calculated using 1D, 2D or 3D 
representations of molecular structures and thus access 
to accurate molecular structures is required. Tools that 
convert chemical names into structures (e.g. NCI/CADD 
Chemical Identifier Resolver [22] or OPSIN [23]) can 
be used, but due to the complexity of chemical naming 
they may fail or derive incorrect/inconsistent structures, 
hence thorough manual checking of structures is highly 
beneficial. Those few relevant freely and easily acces-
sible resources that do provide chemical structures for 
download, such as ChEMBL, HMDB and Drugbank, all 
have different aims and contents (collections of bioac-
tivity data, metabolite data and drug data, respectively). 
Furthermore, their transporter substrate-related content 
and transporter specific metadata is in general limited. In 
a recent study that is most related to the current work, 
Sedykh et  al. [24] collected and published a significant 
amount of data pertaining to substrates and modulators 
of transport proteins with the aim of building predic-
tive models for several transporters. Our efforts over-
lap, extend and complement theirs. In a single resource, 
which is not limited to drugs and only positive results, we 
include cheminformatics-specific data and functionality 
and also protein tissue expression levels and transporter 
locations in tissues that are often missing in other com-
parable databases.
Here we describe Metrabase, in which we offer easily 
accessible data on small molecule transport and metab-
olism, publicly available and useful for computational 
analyses and modeling.
Both metabolism and transport are key elements 
defining the bioavailability and biological activity of 
molecules, i.e. their adverse and therapeutic effects. 
Membrane transport proteins are a large and diverse 
group of proteins that are responsible for transporting 
a very diverse collection of molecules, including ions 
and small molecules across biological membranes. This 
can be observed in a relatively low-throughput fash-
ion (transporters or carriers, including ATP-powered 
pumps) and also in a high-throughput fashion, e.g. up to 
108 water molecules or ions per second (channels) [25]. 
Metrabase includes a selection of efflux and influx trans-
porters from the ABC [26] and SLC [7] families of trans-
porters. They have attracted significant interest in recent 
years [27] and are also included in the revised guidance 
of the US Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) [28] for the approval 
of drugs. In the area of metabolism, Metrabase contains a 
limited set of the cytochrome P450 isozymes (CYPs) that 
have been selected as a major group of xenobiotic metab-
olizing enzymes [29]. Since drug absorption and excre-
tion are influenced by both transport and metabolism, 
transporters and drug metabolizing enzymes can serve 
as a coordinated export system for toxic compounds and 
drugs, i.e. as a protective mechanism. Metrabase aims to 
provide comprehensive structural, physicochemical and 
biological data that can be used to infer the relationships 
between these transporters/enzymes and their ligands 
and its first release is presented here.
Construction and content
Metrabase v1.0 includes interaction data on 20 transport-
ers and 13 CYPs. However, the major focus of this first 
version of the database is on transport proteins: spe-
cifically, on their interactions with small molecules that 
were experimentally found to be (or not to be) substrates. 
Data held in Metrabase was manually extracted from the 
published literature and supplemented with data inte-
grated from other available resources (Figure  1). The 
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literature search, carried out using resources and tools 
such as PubMed, SciFinder, Web of Knowledge, Google, 
Google Scholar and iHOP [30], primarily involved scan-
ning for reports of transporter (non-)substrates. Protein 
synonyms given in the ‘protein_synonyms’ database table 
were used to ensure a comprehensive coverage of the 
search space where needed. If the search returned pub-
lications describing action types other than substrate 
or non-substrate, the data was or was not extracted at 
the curator’s discretion. Manual data extraction was car-
ried out by thirteen supervised undergraduate second 
and third year Natural Sciences students of the Univer-
sity of Cambridge (with specialization in chemistry and 
biochemistry). Each curator underwent induction includ-
ing reading background reviews on transporters and 
metabolism and an explanation of the literature review 
process. The curation process involved reading scien-
tific articles (abstracts and full texts) to ensure that the 
correct action type was assigned to the interacting small 
molecule and then transferring the data of interest into 
an electronic form. Two curators were involved in data 
extraction and verification from a single publication, each 
person performing one or the other task, but not both 
tasks for the same record. Special attention was given to 
the accuracy of chemical structures: three curators veri-
fied a single structure. Protein, compound, action type, 
publication and organism (to which the protein belongs) 
were extracted as a minimum, while the additional data 
(as described below) were extracted at a curator’s discre-
tion if the data was available in the publication.
A summary of the transporter-related Metrabase 
content is shown in Table  1. The principal content is 
associated with 13 of 20 transporters (MDR1, BCRP1, 
PEPT1, MRP1-4, OCT1, OATP1B1, OATP2B1, 
OATP1B3, OATP1A2 and ASBT), while the remaining 7 
transporters (OATP3A1, OATP4A1, MCT1, OATP2A1, 
OSTα/OSTβ, GLUT1 and LAT1) have many fewer asso-
ciated records (less than 20 substrates/non-substrates). 
This initial selection of transporters was mainly directed 
by the guidelines of the International Transporter Con-
sortium [27]—membrane transporters considered to 
have a role in drug absorption and disposition (distri-
bution and elimination), therapeutic efficacy and safety 
(i.e. toxicity) were included. The total number of trans-
porter-related activity records is substantial, totaling 
11,143 records. The CYP-related content of Metrabase 
v1.0 is currently, however, limited to only 506 records 
for all the 13 CYP isoenzymes (3A4, 2S1, 2W1, 4B1, 
2D6, 2C19, 2C9, 2E1, 1A2, 1A1, 1B1, 2C8 and 3A5). This 
selection of CYPs includes the major drug metabolizing 
isoforms (about 95% of the drugs are affected by them) 
and the isoforms expressed in the skin. The latter cate-
gory includes mainly CYPs for which there is very little 
relevant experimental data published. The total num-
bers of compounds interacting with the 20 transporters 
and 13 CYPs are 3,307 and 212 respectively; these were 
compiled from 1,211 publications. On the biological 
side, Metrabase v1.0 also includes 1,087 records of trans-
porter tissue expression levels manually extracted from 
66 publications. We include the expression data, because 
the expression levels influence the capacity of transport-
ers under different physiological and pathophysiologi-
cal conditions. If, for example, we want to increase drug 
absorption using a transporter, then not only its substrate 
specificity, but also expression profile needs to be con-
sidered. In drug development, transporters expressed in 
the intestine, liver, kidney and blood–brain barrier are 
of particular interest. The overall database structure is 
shown in Figure 2.
Activities
The key information held in the ‘activities’ table of the data-
base covers the interactions between proteins and chemi-
cal compounds, indicating the compound action type as 
either substrate, non-substrate, inducer, non-inducer, 
repressor, inhibitor, non-inhibitor, stimulator or binder. In 
this work we define them as follows. Substrates are sub-
stances that are transported (by transporters) or catalyzed 
(by enzymes), while non-substrates are substances that 
were experimentally tested and found not to be substrates 
of a particular transporter or enzyme. Modulators (induc-
ers, stimulators, inhibitors and repressors) are substances 
that alter the ability of a transporter to transport a substrate 
or alter the ability of an enzyme to metabolize a substrate. 
Inducers, non-inducers and repressors (associated with 
Figure 1 Fractions of Metrabase interaction records per data source. 
The total number of records is 11,649. ‘Pgp dataset’ and ‘HITDB data-
set’ refer to the data taken from Poongavanam et al. [31] and Sedykh 
et al. [24] respectively. All the interaction data contained in Metrabase 
was extracted from the published literature: where datasource is 
‘literature’, the data was extracted by members of the Metrabase 
Development Team.
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increased, unchanged and decreased levels of expression, 
respectively) belong to the compound action types related 
to protein expression, while inhibitors, non-inhibitors and 
stimulators (decreased, unchanged and increased protein 
activity, respectively) belong to the group of action types 
related to protein activity (Table  2). Care must be taken 
with respect to the current status of the inhibition records, 
since depending on the threshold used (e.g. percentage 
inhibition) some of the compounds annotated as ‘inhibi-
tors’ can be regarded as ‘non-inhibitors’ and vice versa. This 
is an active area of research and is planned to be further 
resolved in subsequent releases of Metrabase.
Table 1 A summary of the transporter-related Metrabase content
The figures quoted show the number of included compounds for their corresponding actions. Sub, nSub, −Mod, nInh, +Mod and nInd refer to substrate, non-sub-
strate, negative modulators (inhibitor and repressor), non-inhibitor, positive modulators (stimulator and inducer) and non-inducer respectively.
Gene Protein Sub nSub −Mod nInh +Mod nInd
ABCB1 MDR1 566 469 311 113 43 18
ABCG2 BCRP1 310 197 616 24 15 2
SLC15A1 PEPT1 247 95 275 26 7 –
ABCC2 MRP2 160 139 170 150 102 25
SLC22A1 OCT1 166 95 293 68 3 –
ABCC1 MRP1 98 91 4 4 – –
SLCO1B1 OATP1B1 97 41 341 50 5 1
SLCO2B1 OATP2B1 48 75 136 203 23 –
SLCO1B3 OATP1B3 59 36 260 55 10 –
ABCC3 MRP3 66 24 47 4 17 5
SLCO1A2 OATP1A2 56 24 50 1 1 –
SLC10A2 ASBT 54 19 11 – – –
ABCC4 MRP4 47 19 – – – –
SLCO3A1 OATP3A1 5 7 6 – – –
SLC16A1 MCT1 8 3 30 1 – –
SLCO4A1 OATP4A1 7 1 4 – – –
SLC2A1 GLUT1 5 1 21 41 – –
SLCO2A1 OATP2A1 5 1 9 3 – –
SLC51A/B OSTα/β 4 2 – – – –
SLC7A5 LAT1 2 – 6 – – –
Figure 2 Metrabase schema. The database tables are grouped according to their context. There are four main tables: ‘activities’, ‘compounds’, 
‘proteins’ and ‘refs’. Chemical structures and proteins are stored in the ‘compounds’ and ‘proteins’ tables respectively. Interactions between chemical 
compounds and proteins are stored in the ‘activities’ table, while the ‘refs’ table contains the publications’ citation information (bibliographic fields). 
An entity relationship diagram showing all the database fields is provided for download along with the database.
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The ‘activities’ table was initialized with data taken 
from the TP-Search [1] and ChEMBL [9] databases, com-
prising 2,388 TP-Search records and 1,167 records hold-
ing action type annotations in ChEMBL versions 12 and 
14. We also integrated the relevant data (1,009 records) 
from the recent publications of Sedykh et  al. [24] and 
Poongavanam et  al. [31]. Every interaction record is 
linked to the publication that provided the relevant data 
point. The current release holds only human-related 
records, but the importance of data related to orthologs 
is indisputable and therefore scheduled to be included 
in subsequent releases. There are five key activity fields: 
cmpd_id, protein_id, action_type, ref_id and species. 
Other ‘activities’ fields holding additional extracted data, 
such as assay descriptions, relevant experimental meas-
urements, cell lines, compound concentrations and the 
substrates used in inhibition assays, may have only been 
partially completed in this release.
Compounds
The total number of compounds with recorded interac-
tion data for both transporters and enzymes is 3,438. 
Their structures are available in MDL molfile format and 
as absolute SMILES strings (in Kekulé form). The stand-
ard InChI and InChI Key strings were computed using 
v1.04 of the InChI software [32]. The great majority of 
the compounds are small organic molecules (containing 
just the following atoms: C, H, O, P, S, N, F, Cl, Br and 
I) and other types (coordination complexes, inorganic 
compounds, metalloid-containing compounds, sele-
nium-containing compounds and polymers) are listed 
in the ‘cmpd_types’ table. Annotations of compounds 
as other types and subtypes, such as ‘natural product’ 
and ‘sesquiterpene’, can also easily be added. Stereoi-
somers, different forms (e.g. a cyclic isomer of glucose) 
and multi-component structures (e.g. irinotecan hydro-
chloride; also including mixtures, such as ivermectin) are 
listed in the ‘cmpd_variants’ table. Where it was not clear 
which component(s) of a multi-component structure are 
responsible for the action, the multi-component struc-
ture was annotated as a mixture (here only the mixture 
has been tested and so the biological activity may reside 
in either one or all of its individual components). Chemi-
cal structures were verified using ChemSpider [33] and 
SciFinder [34] as “gold standards”. The ‘properties’ table 
contains selected molecular properties, which were cal-
culated/predicted for all structures (molecular mass) or 
just the small organic single-component structures (a 
selection of the constitutional descriptors, log P and log 
D) using ChemAxon’s Calculator (cxcalc) [35]. Additional 
properties, either calculated/predicted or experimental, 
can easily be added (and defined in the ‘property_types’ 
table before the records can be inserted). The database is 
therefore also expandable by other users who may wish 
to insert their own data or add metadata to the records.
Proteins
The proteins contained in Metrabase are categorized 
as either transporters or enzymes and are provided 
with symbols and names approved by the HUGO Gene 
Nomenclature Committee (HGNC) [36], as well as Uni-
Prot [16] accession identifiers. Protein sequences for the 
indicated isoforms were included from UniProt. Metra-
base also contains qualitative information about protein 
expression levels across healthy human tissues. Part of 
this data is based on immunohistochemistry using tis-
sue microarrays and comes from the normal_tissue.
csv file of the Human Protein Atlas (HPA) v9.0 [37]. All 
other expression records contain data extracted from the 
literature.
Utility and discussion
Database access
Metrabase is accessible via an online user interface at 
http://www-metrabase.ch.cam.ac.uk, and allows users to 
search the database by protein or compound. Search by 
protein is the main feature (Figure 3). It allows retrieval 
of all compounds interacting with the selected protein 
and shows their action types and links to the literature 
references from which the data originated. Search by 
compound allows name, structure, substructure and sim-
ilarity searches. These are supported by the ChemDoodle 
2D sketcher [38] for structure drawing and the Mychem 
cartridge (for MySQL) [39], which performs cheminfor-
matics-specific functions. The similarity search employs 
the FP2 fingerprint of Open Babel [40] and the exact 
search compares InChI strings. Furthermore, users can 
retrieve tissue expression data and access information 
held in the UniProt and HGNC databases following 
the links provided in the list of the proteins. A data-
base dump is also available for download enabling users 
to install their own local copy of the database. MySQL 
Workbench can be used as an interface: even though 
knowledge of SQL may not be required to display records 
of all tables and save them in other formats, such as TSV 
Table 2 A list of the action types in Metrabase
Action types
Protein activity (transport or catalysis) Substrate
Non-substrate
Compound activity (affecting protein  
activity/expression)
Inhibitor/repressor 
(negative modulators)
Stimulator/inducer 
(positive modulators)
Non-inhibitor/non-inducer 
(inactive compounds)
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or CSV, it is needed to fully exploit the database in this 
manner.
The transporter substrate dataset
We aim to provide a version of the transporter substrate 
dataset (MBTPsubDS) as a supplement to each Metra-
base release (Figure 4). The first version of MBTPsubDS, 
based on Metrabase v1.0 and including datasets MBT-
PsubDS1_0 (Additional file  1) and MBTPsubDS1_0a 
(Additional file 2), was created using an in-house Python 
script and contains unique substrate and non-substrate 
records, which were processed to facilitate human trans-
porter data analysis and predictive modeling. Mixtures, 
coordination complexes and other metal-containing 
compounds, inorganic compounds, polymers and met-
alloid-containing (including selenium-containing) com-
pounds (as annotated in the ‘cmpd_types’ table) were 
removed. Only small molecules defined as those with a 
molecular mass of ≤1 kDa were retained. Stereoisomers 
were not considered (of course, this is an area for future 
Figure 3 Search by protein example: retrieval of compounds tested for transport by OATP1B1. The Metrabase homepage is shown at the top. 
Results of searches are displayed in tables and can be downloaded in TSV (tab-separated values) and SD files.
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development as stereoisomers can have substantially dif-
ferent bioactivities) and all the remaining multi-compo-
nent structures were replaced by their single-component 
counterparts as given in the ‘cmpd_variants’ table. Effec-
tively, this corresponds to the usually applied procedure 
of keeping the largest component of each structure, 
except that this procedure is based on either the number 
of atoms or molecular mass and can thus lead to reten-
tion of unwanted components. Finally, all the duplicates 
formed due to ignored stereoisomerism and salt compo-
nents were removed.
Datasets MBTPsubDS1_0 and MBTPsubDS1_0a 
contain 2,901 and 2,913 small molecule-transporter 
interaction records respectively. The latter dataset is a 
slightly extended version of the former dataset. All the 
interactions involving conflicting action types (where a 
compound was found to be both a substrate and a non-
substrate of a single transporter) were removed from 
the former dataset, whereas the latter dataset contains a 
few of the compound-protein pairs corresponding to the 
resolved conflicting action types (where upon inspection 
we have defaulted to considering the compound as either 
a substrate or a non-substrate depending on the num-
ber of publications supporting each type). Compounds 
of the MBTPsubDS dataset make a diverse collection of 
molecular structures covering wide ranges of property 
values, however they are mostly lipophilic compounds, 
with 85% of the compounds possessing calculated log 
P  >  0. Distributions of log P and several other selected 
molecular properties are shown in Figure 5.
Usage
Structured and high quality experimental data stored in a 
container, such as a relational database, can facilitate easy 
computational processing, thus allowing for high quality 
information/knowledge to be inferred by computational 
analyses. In cheminformatics and other disciplines deal-
ing with small molecules, in particular the correctness of 
chemical structures is vital [41, 42]. As stated by Young 
et al. [41], small structural errors can lead to significant 
errors in predictions and so the predictivity of QSAR 
models could be substantially increased by thorough 
curation.
Data mining using resources like Metrabase can be 
employed to understand, for example, transporter func-
tion or the promiscuous nature of compounds bind-
ing to transporters competitively or non-competitively. 
Transporters can be highly promiscuous proteins trans-
porting structurally quite diverse compounds across cell 
membranes at rates of hundreds to tens of thousands 
Figure 4 A diagram depicting the steps in the creation of the transporter substrate dataset. The first version of MBTPsubDS was generated using 
an in-house Python script to process the data retrieved from Metrabase. Mixtures, metal-, metalloid- and selenium- containing compounds and 
polymers were identified using the metrabase.cmpd_types table and compounds with molecular mass >1 kDa were identified using the metra-
base.properties table.
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per second [25]. We can infer the relationships between 
transporters and their ligands, to see what kind of sub-
strates they prefer and do not prefer, and why. The 
intended purpose of the database is also to facilitate in 
silico predictive modeling, e.g. tissue distribution of a 
new compound (and thus its toxicity potential assessed 
within the scope of the predicted tissue accumulation).
MBTPsubDS1_0 and MBTPsubDS1_0a datasets were 
created using the data contained in Metrabase v1.0 to 
allow a structural analysis of the transporter substrates 
and generation of transporter models that can predict 
whether or not a compound is a substrate of a range of 
efflux and uptake transporters (this work will be pub-
lished elsewhere). All the required information (e.g. 
stereoisomers, metal complexes or multi-component 
structures linked to their single-component counter-
parts) is held in the database, and thus only a processing 
script written in a suitable programming language is suf-
ficient to produce a version of MBTPsubDS.
The number of substrates (or non-substrates) shared 
between transporters is shown in Figure  6. It can be 
seen that in the current dataset there is not enough 
data to explore the extent to which similarities in trans-
porter sequences determine similarities in compounds 
transported, since having a more complete data matrix 
would be required—a selection of compounds tested 
against a selection of transporters in an all-to-all fashion 
would be ideal. Furthermore, this dataset contains quite 
a diverse set of transporters with only OATP1B1 and 
OATP1B3 sharing a high sequence similarity/identity 
Figure 5 Histograms showing distributions of selected properties for all compounds contained in the MBTPsubDS1_0a dataset. HBA, HBD and 
TPSA stand for hydrogen bond acceptor, hydrogen bond donor and topological polar surface area respectively.
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of 87.1%/78.5% (global pairwise sequence alignment 
was obtained using EMBOSS Stretcher v6.6.0 [43] with 
default parameters) followed by the ABCC subfamily 
(ABCC1 and ABCC3 have sequence similarity/identity of 
73.4%/56.7%). We could perhaps perceive from Figure 6 
initial support for the assumption that it is more likely 
that a substrate of SLCO1B1 will also be a substrate of 
SLCO1B3 than other transporters. However, with many 
data points missing, this could also be a consequence 
of experimental assays being carried out more often for 
transporters belonging to the same family (if more than 
one transporter was explored in the experiment).
The following two lists summarize the main intended 
uses of Metrabase (an example is shown in Figure 3):
  • read across using similarity to compounds in the 
database,
  • given a protein, show interacting compounds 
(including those where interaction was tested but not 
observed),
  • given a compound, show interacting proteins 
(including those where interaction was tested but not 
observed),
  • given a protein, list its tissue expression levels (quali-
tative only),
  • given a tissue, list protein expression levels for this 
tissue (qualitative only);
and its benefits:
  • action type is specified for all Metrabase compounds,
  • negative action types (incl. inactive compounds) are 
included,
  • chemical structures are included in the database, 
along with compound names,
  • cell lines are specified for substrate records linked to 
primary literature references and we aim to expand 
this for all the ‘activities’ records,
  • records are linked to the publications, which the 
data was extracted from (allowing thus for easier 
verification and for getting further information) 
and
  • Metrabase is a publicly available and fully accessible 
resource.
Use case 1: identification of drug–drug interactions 
for atorvastatin
Atorvastatin (Lipitor) is a highly prescribed statin for 
the treatment of high blood cholesterol and for preven-
tion of incidents that are associated with cardiovascu-
lar diseases. The mechanism of action of atorvastatin is 
inhibition of HMG-CoA reductase, and it is also known 
to be associated with other proteins, among them trans-
porters [44]. In this use case we show how to identify the 
transporters with which atorvastatin is associated, and 
cross-reference them with potential inhibitors of these 
transporters, which could result in high accumulation of 
the drug and potential toxic drug–drug interactions by 
increased bioavailability of the drug [45].
Figure 6 The number of shared substrates and non-substrates between the 13 selected transporters. Transporters can be highly promiscuous with 
overlapping compound recognition patterns. These two matrices show the number of shared substrates (left) and non-substrates (right) within the 
MBTPsubDS1_0a dataset.
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Method
1. In the “Search by compound” section, run an exact 
search for “atorvastatin”.
2. The results show that atorvastatin was found to 
be a substrate of six transporters (MDR1, MCT1, 
OATP1B1, OATP1B3, OATP1A2, OATP2B1) and 
also an inhibitor of five transporters (MDR1, BCRP1, 
OATP1B1, OATP1B3, OATP2B1) with seven refer-
ences indicating that it is an OATP1B1 substrate.
3. In “Search by protein” select “OATP1B1” and both 
“inhibitor” and “inducer”.
4. The results reveal a number of potential drug–drug 
interactions, among them several references to 
potentially strong inhibitors, such as cyclosporine.
The results of an exact search for cyclosporine (“Search 
by compound”) reveal a large number of references in 
support of cyclosporine being an inhibitor of several 
transporters, including 12 references for OATP1B1 inhi-
bition, suggesting that the dose of atorvastatin should be 
lowered when co-administered with cyclosporine.
Use case 2: Exploring potential drug‑food interactions 
with green tea
Green tea is known to contain high amounts of flavan-
3-ols, including catechins of which (−)-epigallocatechin-
gallate (EGCG) is the most abundant catechin [46]. In 
this use case we are employing the molecular structure of 
catechin to search for similar compounds with annotated 
transporter interactions. If found this might indicate 
potential adverse nutrient-drug interactions instigated 
by consumption of green tea coupled together with drug 
intake.
Method
1. In the “Search by compound” section run a 
similarity search using the SMILES represen-
tation of the catechin molecular structure, 
(c1cc(c(cc1[C@@H]2[C@H](Cc3c(cc(cc3O2)O)O)O)
O)O), and Tanimoto coefficient (TC) cut-off of 0.3.
2. The results show 317 hits found in Metrabase that 
exhibit structural similarity to the catechin chemi-
cal structure. The hits include known catechins such 
as EGCG (TC = 0.823) and epicatechin (TC = 1.0), 
drugs such as nadolol (TC = 0.511) and troglitazone 
(TC  =  0.457), and other natural products such as 
phlorizin (TC = 0.457).
3. Metrabase shows that EGCG has been found to be 
extensively associated with transporters: as a sub-
strate of MRP1/2, OATP1B3 and OATP1A2, as a 
non-substrate of MDR1, OATP1B1, OATP2B1 and 
as an inhibitor of several OATPs such as OATP1A2, 
OATP1B1 and OATP2B1.
4. Nadolol is annotated as a substrate of MDR1 and 
OATP1A2 and as an inhibitor of BCRP1.
5. This potential interaction suggests that uptake of 
nadolol may be affected by co-administration with 
green tea and thus result in low plasma concentration 
due to the inhibition of its uptake transporter.
This nutrient-drug interaction was highlighted in a 
recent publication (not included in this version of Metra-
base), which reported low intestinal uptake of nadolol 
by inhibition of OATP1A2-mediated uptake caused by 
green tea ingestion [47].
Future development plans
Further data curation, comprehensive data coverage and 
improvements are planned for subsequent Metrabase 
releases, as well as inclusion of additional biochemical 
annotations (especially with respect to sequence variants 
due to their importance in phenotypic variation, e.g. in 
drug metabolism). Moreover, we aim to include species 
other than human, as well as protein expression levels for 
diseased tissues, as this is highly relevant in the context of 
drug discovery. Even though the first release of Metrabase 
includes calculated molecular properties only, the ‘prop-
erties.type’ field values of ‘c’ and ‘e’ are proposed to desig-
nate calculated and experimental properties respectively, 
for possible future addition of experimental properties. 
The additional ‘activities’ fields, although incomplete as 
indicated in the Activities section above, were included 
in the first release and are planned to be completed in 
the subsequent releases. The selection of transporters, 
which was mainly steered by the guidelines of the Inter-
national Transporter Consortium [27], is planned to be 
extended. We first aim to include additional data points 
for the 13 Metrabase CYPs before extending the protein 
list to include other Phase I, II and III enzymes involved 
in xenobiotic metabolism. Further improvements to the 
web interface can also be expected.
Conclusions
Metrabase offers structured and freely accessible manu-
ally extracted data on interactions between transport and 
metabolism related proteins and chemical compounds 
(the first version’s emphasis being on the transport pro-
teins). It provides not only actions and measured activi-
ties, but also chemical structural information, tissue 
expression data and negative action types, which are 
essential in modeling activity. In particular, by creat-
ing accessible data that can be used in e.g. biochemistry, 
pharmacology and toxicology, we hope diverse research 
communities will find Metrabase useful and valuable. The 
availability of the raw data in an easily accessible form 
will allow other research workers in the field to easily 
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include this data in collections of transporter/metabo-
lism datasets as well as allow easy integration with other 
programs and services.
Availability and requirements
Metrabase is accessible via an online user interface at 
http://www-metrabase.ch.cam.ac.uk. Users can also 
install their own local copy of the database, for which a 
MySQL server installation is required. The Download 
section provides access to a MySQL dump of Metra-
base, its schema, a user manual providing comprehensive 
information and versions of the transporter substrate 
dataset, i.e. MBTPsubDS. Metrabase version 1.0 is freely 
available under a Creative Commons Attribution-Share-
Alike 4.0 International license. However, the integrated 
data retains the licensing of the original data sources. 
The TP-Search and ChEMBL records may have been 
modified and augmented based on literature revision or 
reinterpretation, while the HPA records were included 
unmodified. The ‘datasource id’ and ‘datasource version’ 
fields indicate the source of each relevant Metrabase 
record.
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